147 related articles for article (PubMed ID: 16046158)
1. Structural model of the Plasmodium CDK, Pfmrk, a novel target for malaria therapeutics.
Peng Y; Keenan SM; Welsh WJ
J Mol Graph Model; 2005 Sep; 24(1):72-80. PubMed ID: 16046158
[TBL] [Abstract][Full Text] [Related]
2. Targeting malaria with specific CDK inhibitors.
Geyer JA; Prigge ST; Waters NC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.
Waters NC; Geyer JA
Expert Opin Ther Targets; 2003 Feb; 7(1):7-17. PubMed ID: 12556199
[TBL] [Abstract][Full Text] [Related]
4. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
[TBL] [Abstract][Full Text] [Related]
5. Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases.
Woodard CL; Li Z; Kathcart AK; Terrell J; Gerena L; Lopez-Sanchez M; Kyle DE; Bhattacharjee AK; Nichols DA; Ellis W; Prigge ST; Geyer JA; Waters NC
J Med Chem; 2003 Aug; 46(18):3877-82. PubMed ID: 12930149
[TBL] [Abstract][Full Text] [Related]
6. Identification of an effector protein and gain-of-function mutants that activate Pfmrk, a malarial cyclin-dependent protein kinase.
Chen Y; Jirage D; Caridha D; Kathcart AK; Cortes EA; Dennull RA; Geyer JA; Prigge ST; Waters NC
Mol Biochem Parasitol; 2006 Sep; 149(1):48-57. PubMed ID: 16737745
[TBL] [Abstract][Full Text] [Related]
7. Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum.
Waters NC; Woodard CL; Prigge ST
Mol Biochem Parasitol; 2000 Mar; 107(1):45-55. PubMed ID: 10717301
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones.
Geyer JA; Keenan SM; Woodard CL; Thompson PA; Gerena L; Nichols DA; Gutteridge CE; Waters NC
Bioorg Med Chem Lett; 2009 Apr; 19(7):1982-5. PubMed ID: 19250824
[TBL] [Abstract][Full Text] [Related]
9. Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization.
Li JL; Robson KJ; Chen JL; Targett GA; Baker DA
Eur J Biochem; 1996 Nov; 241(3):805-13. PubMed ID: 8944769
[TBL] [Abstract][Full Text] [Related]
10. The malarial CDK Pfmrk and its effector PfMAT1 phosphorylate DNA replication proteins and co-localize in the nucleus.
Jirage D; Chen Y; Caridha D; O'Neil MT; Eyase F; Witola WH; Mamoun CB; Waters NC
Mol Biochem Parasitol; 2010 Jul; 172(1):9-18. PubMed ID: 20332005
[TBL] [Abstract][Full Text] [Related]
11. The Malaria Parasite Cyclin H Homolog PfCyc1 Is Required for Efficient Cytokinesis in Blood-Stage
Robbins JA; Absalon S; Streva VA; Dvorin JD
mBio; 2017 Jun; 8(3):. PubMed ID: 28611247
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
Keenan SM; Welsh WJ
J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
[TBL] [Abstract][Full Text] [Related]
13. Influence of human p16(INK4) and p21(CIP1) on the in vitro activity of recombinant Plasmodium falciparum cyclin-dependent protein kinases.
Li Z; Le Roch K; Geyer JA; Woodard CL; Prigge ST; Koh J; Doerig C; Waters NC
Biochem Biophys Res Commun; 2001 Nov; 288(5):1207-11. PubMed ID: 11700040
[TBL] [Abstract][Full Text] [Related]
14. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors.
Keenan SM; Geyer JA; Welsh WJ; Prigge ST; Waters NC
Comb Chem High Throughput Screen; 2005 Feb; 8(1):27-38. PubMed ID: 15720195
[TBL] [Abstract][Full Text] [Related]
15. In silico three-dimensional pharmacophores for aiding the discovery of the Pfmrk (Plasmodium cyclin-dependent protein kinases) specific inhibitors for the therapeutic treatment of malaria.
Bhattacharjee AK
Expert Opin Drug Discov; 2007 Aug; 2(8):1115-27. PubMed ID: 23484876
[TBL] [Abstract][Full Text] [Related]
16. Molecular models of protein kinase 6 from Plasmodium falciparum.
Manhani KK; Arcuri HA; da Silveira NJ; Uchôa HB; de Azevedo WF; Canduri F
J Mol Model; 2005 Dec; 12(1):42-8. PubMed ID: 16096806
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk.
Woodard CL; Keenan SM; Gerena L; Welsh WJ; Geyer JA; Waters NC
Bioorg Med Chem Lett; 2007 Sep; 17(17):4961-6. PubMed ID: 17588749
[TBL] [Abstract][Full Text] [Related]
18. Plasmodium falciparum encodes a conserved active inhibitor-2 for Protein Phosphatase type 1: perspectives for novel anti-plasmodial therapy.
Fréville A; Cailliau-Maggio K; Pierrot C; Tellier G; Kalamou H; Lafitte S; Martoriati A; Pierce RJ; Bodart JF; Khalife J
BMC Biol; 2013 Jul; 11():80. PubMed ID: 23837822
[TBL] [Abstract][Full Text] [Related]
19. Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
Caridha D; Kathcart AK; Jirage D; Waters NC
Bioorg Med Chem Lett; 2010 Jul; 20(13):3863-7. PubMed ID: 20627564
[TBL] [Abstract][Full Text] [Related]
20. In silico characterization and molecular dynamics simulation of Pfcyc-1, a cyclin homolog of Plasmodium falciparum.
Kaushik A; Subramaniam S; Gupta D
J Biomol Struct Dyn; 2014; 32(10):1624-33. PubMed ID: 23998890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
